LCC
VYGR icon

Lincoln Capital Corp’s Voyager Therapeutics VYGR Stock Holding History

Lincoln Capital Corp’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,000
Closed -$47K – 66
2021
Q1 		$47K Hold
10,000
– – 0.03% 58
2020
Q4 		$72K Sell
10,000
-1,000
-9% -$9.61K 0.05% 53
2020
Q3 		$117K Buy
+11,000
New +$129K 0.09% 51

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Lincoln Capital Corp's VYGR Position: Q2 2021 in Review

Lincoln Capital Corp sold out of Voyager Therapeutics (VYGR) in Q2 2021, closing a stake of 10,000 shares — an estimated $47K sold.

Lincoln Capital Corp first reported a position in VYGR in Q3 2020 and held it in 3 quarters. The position peaked at $117K in Q3 2020. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2021.

  • Lincoln Capital Corp reported no remaining Voyager Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Lincoln Capital Corp sold 10,000 Voyager Therapeutics shares in Q2 2021, an estimated $47K.
  • Lincoln Capital Corp first reported a position in Voyager Therapeutics in Q3 2020 and held it in 3 quarters.
  • Lincoln Capital Corp's Voyager Therapeutics position peaked at $117K in Q3 2020.
  • 78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2021.

Based on Lincoln Capital Corp's 13F filing for Q2 2021, filed 22 Jul 2021.